Hydroxychloroquine before radiation and chemo for NPC
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether taking hydroxychloroquine (HCQ) before standard radiation and chemo can help treat advanced nasopharyngeal cancer. It is for patients who have not yet started any cancer therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have nasopharyngeal cancer (a type of head and neck cancer).
- You cannot have had any cancer treatments before joining this trial.
- You must be willing to sign a consent form agreeing to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to give radiation therapy after immunotherapy and chemotherapy for people with advanced nasopharyngeal cancer (NPC) that has partially shrunk. It aims to see if a different radiation schedule works better and has fewer side effects.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This trial compares two different chemotherapy combinations given before radiation for nasopharyngeal cancer. It is for patients with advanced but not metastatic disease who are in good overall health.
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
This trial tests whether a specific chemotherapy drug (nab-paclitaxel) given along with targeted radiation therapy can help people with stage III or IVa nasopharyngeal cancer. The goal is to improve treatment outcomes while managing side effects.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.